HCN1 ion channel targeting

Akelos Inc. is an innovative research-based biotechnology/biopharmaceutical clinical company focused on translating innovative science into treatment. It is developing novel non-narcotic (non-opioid) drugs for the treatment of neuropathic pain, with a non-opioid drug candidate in pre-clinical development. Its development efforts focus on the HCN1 ion channel in primary sensory neurons. The company is partially funded by the National Institutes of Health (NIH) and has exclusively licensed intellectual property from Cornell University.

Read more

biopharmaceutical researchpatent licensingpre-clinical drug development